Don't take our word for it,
read what our clients say about us

Controlled Substances Squared, Expedichem and DG Assessor are used and trusted by many of the worlds top Pharmaceutical companies, chemicals suppliers, CROs and regulators.

Our clients include AstraZeneca, GlaxoSmithKline, Roche, Boehringer Ingelheim, Merck, UK HomeOffice, Sygnature Discovery, UCB, LGC Standards, Cayman Chemical and Biosynth. Below you can read a small selection of the amazing feedback we've received and which our clients have kindly let us publish.

 

“We implemented Controlled Substances Squared (CS2) in our workflow several years ago. The software checks compounds upon registration from our chemists internally and externally. Each compound is then treated accordingly by our compound management staff. This software has had a great impact in helping us monitoring our controlled substances across multiple jurisdictions, which was for us a difficult process in the past.”

Director Research Informatics & Operations, Lundbeck

 

"Boehringer Ingelheim use Scitegrity’s Controlled Substances Squared system to provide controlled substance compliance at all stages of R&D operation. The weekly legislation updates that are automatically checked against the compound collections ensure permanent compliance with the latest laws, while its integration with synthesis and procurement systems ensure all new compounds are checked.”

Head of Compound Management, Boehringer Ingelheim


“We have utilised Scitegrity’s Controlled Substances Squared (CS2) solution for several years now as our enterprise-wide mechanism for identifying controlled substances. Scitegrity’s staff continually display outstanding customer focus in working with us for integrations with internal applications, answering questions about functionality, and anything else that comes up-all in a timely fashion. Their expertise in the regulations has also been invaluable, as they provide alerts to regulatory changes and are available to answer specific queries that arise internally from scientists or management. I have been very pleased with the decision to work with Scitegrity and would endorse them, and their products, to others.”

Controlled Chemicals Lead, GSK


“The software is great (Compliance Hub, including Controlled Substances Squared & ExpediChem) and I have no idea how we managed before”

Deputy Head of Research Products, BioSynth 

 

“As part of Catalyst efforts to develop a new CNS drug, Scitegrity performed a quantitative chemical similarity test between our drug an all schedule I through V controlled substances.  In a matter of weeks, Scitegrity completed this work and prepared a report suitable for NDA submission and review by the FDA’s controlled substances staff.  In addition, the speed and high quality, it was conducted with minimal oversight and interaction with Scitegrity.  It is nice to have a contractor that just gets things done right and leaves one less thing to worry about during the drug development process.”

Steven Miller, Chief Scientific Officer, Catalyst Pharmaceuticals


"In relation to development and filing of a new CNS drug, we used the experience and expertise of Scitegrity to perform an analysis of the structural similarity of our compound to US schedule 1 to 5 compounds as part of Lundbeck’s wider Drug Abuse Potential Assessment. Scitegrity provided expert input to the assessment, provided a high quality report and allowed us to progress development in a timely manner."

Safety Pharmacology Lead,  Lundbeck A/S  

 

Trusted by our Clients

cayman
LGC_standards-1
Roche
gsk
Boehringer
Merck_logo
HomeOffice logo
sygnature_logo
UCB
AstraZeneca
Biosynth_logo_new

What our clients are saying

Lundbeck_Logo

Director Research Informatics & Operations

LundBeck
“We implemented Controlled Substances Squared (CS2) in our workflow about 2 years ago. The software checks compounds upon registration from our chemists internally and externally. Each compound is then treated accordingly by our compound management staff. This software has had a great impact in helping us monitoring our controlled substances across multiple jurisdictions, which was for us a difficult process in the past.”
user

Controlled Chemicals Lead

Big 10 Pharma Company
“We have utilised Scitegrity’s Controlled Substances Squared (CS2) solution for several years now as our enterprise-wide mechanism for identifying controlled substances. Scitegrity’s staff continually display outstanding customer focus in working with us for integrations with internal applications, answering questions about functionality, and anything else that comes up-all in a timely fashion. Their expertise in the regulations has also been invaluable, as they provide alerts to regulatory changes and are available to answer specific queries that arise internally from scientists or management. I have been very pleased with the decision to work with Scitegrity and would endorse them, and their products, to others.”
Catalyst_logo_color

Steven Miller, Chief Scientific Officer

Catalyst Pharmaceuticals
“As part of Catalyst efforts to develop a new CNS drug, Scitegrity performed a quantitative chemical similarity test between our drug an all schedule I through V controlled substances.  In a matter of weeks, Scitegrity completed this work and prepared a report suitable for NDA submission and review by the FDA’s controlled substances staff.  In addition, the speed and high quality, it was conducted with minimal oversight and interaction with Scitegrity.  It is nice to have a contractor that just gets things done right and leaves one less thing to worry about during the drug development process.”
user

Deputy Head of Research Products, BioSynth

“The software is great (Compliance Hub, including Controlled Substances Squared & ExpediChem) and I have no idea how we managed before”
user

Head of Compound Management

Boehringer Ingelheim
"Boehringer Ingelheim use Scitegrity’s Controlled Substances Squared system to provide controlled substance compliance at all stages of R&D operation. The weekly legislation updates that are automatically checked against the compound collections ensure permanent compliance with the latest laws, while its integration with synthesis and procurement systems ensure all new compounds are checked.” - Head of Compound Management, Boehringer
user

Lundbeck A/S

Safety Pharmacology
"In relation to development and filing of a new CNS drug, we used the experience and expertise of Scitegrity to perform an analysis of the structural similarity of our compound to US schedule 1 to 5 compounds as part of Lundbeck’s wider Drug Abuse Potential Assessment. Scitegrity provided expert input to the assessment, provided a high quality report and allowed us to progress development in a timely manner."
user

William Hapworth

President, Neuritek Therapeutics AG
"In support of Neuritek’s development of a new CNS drug, Scitegrity performed a comprehensive chemical similarity assessment to compounds controlled under Schedules 1-5 of the United States Controlled Substances Act. The work was done quickly, precisely and with outstanding diligence. The interactions with the Scitegrity team were nothing but pleasant. The report was clear, provided the necessary data to answer the scientific questions and supported our efforts of de-risking and progressing with our drug development program"